Compare · KRBP vs MEHA
KRBP vs MEHA
Side-by-side comparison of Kiromic BioPharma Inc. (KRBP) and Functional Brands Inc. (MEHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRBP and MEHA operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- Company
- Kiromic BioPharma Inc.
- Functional Brands Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Kiromic BioPharma Inc.
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Latest KRBP
- Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Kiromic BioPharma Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form S-1/A filed by Kiromic BioPharma Inc.
- Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
- SEC Form 10-K filed by Kiromic BioPharma Inc.
- Amendment: Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
- SEC Form S-1 filed by Kiromic BioPharma Inc.
- Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
Latest MEHA
- Functional Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Functional Brands Announces Second Quarter 2026 Financial Results
- SEC Form 25-NSE filed by Functional Brands Inc.
- Functional Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- Functional Brands Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Functional Brands Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Functional Brands Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Functional Brands Inc.
- SEC Form DEFA14A filed by Functional Brands Inc.
- Amendment: Functional Brands Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits